Alzheimer DiseasePharmacogWP3NCT02899403
Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003
A study testing Rapid Visual Information Processing (RVIP) test in people with Alzheimer Disease and ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder), run by University Hospital, Lille at 1 site in France.
Trial summary
In the perspective to better evaluate the efficacy of new treatment strategies for Alzheimer disease (AD), it appears important to develop experimental paradigms to precisely measure cognitive endpoints/biomarkers that may be used in healthy volunteers as tools to validate drug efficacy profile. Read more about this study
- Who is it for?
- Ages 18 to 30 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Alzheimer Disease, ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder)
- What is being tested?
- Rapid Visual Information Processing (RVIP) test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteFrance
- Study dates
- 19 May 2017to 31 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Right-handed
- In good health on the basis of the medical interview (medical history, symptoms), the physical examination and vital signs
- Non smoker and with no history of drug or alcohol abuse
- Without chronic treatment
- With normal hearing and normal vision including color (with correction)
- French speaker and able to understand the test instructions
- Has provided written informed consent
- Able to read and understand the Information Form and comply with the protocol instructions and restrictions
Who cannot join
- Cognitive impairment (MoCA < 26)
- Cognitive complaint (MacNair Scale > 15)
- History of brain disease (severe brain trauma, stroke, cerebral tumor…) or current cerebral disease
- Major medical or surgical history
- Current chronic disease
- Vascular or metabolic risk factor
Show all 12Show fewer
- History or current mental disease or addiction (MINI)
- Family history of young onset dementia
- Family history of chronic or severe neurological or mental disease (first degree relatives)
- In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason
- Participates to another clinical trial or is still being within a washout period of a previous clinical trial
- Already exposed to cognitive tests used in this study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -A Pilot Study WP3 P003
In the perspective to better evaluate the efficacy of new treatment strategies for Alzheimer disease (AD), it appears important to develop experimental paradigms to precisely measure cognitive endpoints/biomarkers that may be used in healthy volunteers as tools to validate drug efficacy profile.
The use of Electroencephalography (EEG) may be, therefore, a good candidate. The purpose of the present study is to use EEG to more precisely explore cognitive processes in healthy subjects, with a particular interest in episodic and working memory functions that are usually altered in both AD and Mild Cognitive Impairment (MCI) as well as to better understand underlying neural mechanisms involved in these processes.
- Being tested
- Rapid Visual Information Processing (RVIP) test
- Keywords
- Cognitive Tasks, Mild Cognitive Impairment, Neurophysiological Correlates, Healthy Volunteers
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rapid Visual Information Processing (RVIP) testOther
Rapid Visual Information Processing is a measure of sustained attention.
| Study group | Role | What they receive |
|---|---|---|
| healthy subjects | Experimental | Not described Receives: Other: Rapid Visual Information Processing (RVIP) test |
What is being measured
The primary outcome is the main question the study is designed to answer.
EEG spectral power during RVIP task as compared to resting state
The Rapid Visual Information Processing (RVIP®) is a test of sustained attention and has proved useful in many studies in which drugs are used to help develop a disease model. It is sensitive to dysfunction in the parietal and frontal lobe areas of the brain
Measured: within 7 days after inclusion ( session1)
Secondary outcomes (5)
EEG spectral power during PRM task as compared to resting state
the Pattern Recognition Memory (PRM®) is a test assessing visual recognition memory, considered as a sensitive measure of medial temporal areas dysfunction. It is a useful tool for assessing patients with MCI and AD
Measured: within 7 days after inclusion ( session1)
RVIP latency of responses
Measured: within 7 days after inclusion ( session1) and within 7days after session 1 (=session2)
PRM number of errors
Measured: within 7 days after inclusion ( session1) and within 7 days after session 1 (=session2)
PRM latency of responses
Measured: within 7 days after inclusion (=session1) and within 7 days after session 1 (=session2)
difference between session 2 and session 1 EEG Spectral power during RVIP task
Measured: at 7 days after session 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2016 (estimated)
- Study start19 May 2017
- Primary completion31 Dec 2020
- Study completion31 Dec 2020
Why it stopped: sponsor decision COVID
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dominique Deplanque, MD, PhD, Principal investigator, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02899403
- Sponsor's protocol ID
- 2013_45
- Other IDs
- 2015-A00046-43
- Acronym
- PharmacogWP3
- Status last verified
- May 2026
- First submitted
- 1 Sep 2016
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -A Pilot Study WP3 P003
- ClinicalTrials.gov ID
- NCT02899403
- Acronym / sponsor ID
- PharmacogWP3 / 2013_45
- Keywords
- Cognitive Tasks, Mild Cognitive Impairment, Neurophysiological Correlates, Healthy Volunteers
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: sponsor decision COVID
- Enrolment
- 6 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- 19 May 2017 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 14 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the perspective to better evaluate the efficacy of new treatment strategies for Alzheimer disease (AD), it appears important to develop experimental paradigms to precisely measure cognitive endpoints/biomarkers that may be used in healthy volunteers as tools to validate drug efficacy profile.
The use of Electroencephalography (EEG) may be, therefore, a good candidate. The purpose of the present study is to use EEG to more precisely explore cognitive processes in healthy subjects, with a particular interest in episodic and working memory functions that are usually altered in both AD and Mild Cognitive Impairment (MCI) as well as to better understand underlying neural mechanisms involved in these processes.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| healthy subjects | Experimental | Other: Rapid Visual Information Processing (RVIP) test |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Right-handed
- In good health on the basis of the medical interview (medical history, symptoms), the physical examination and vital signs
- Non smoker and with no history of drug or alcohol abuse
- Without chronic treatment
- With normal hearing and normal vision including color (with correction)
Key exclusion criteria (12 listed)
- Cognitive impairment (MoCA < 26)
- Cognitive complaint (MacNair Scale > 15)
- History of brain disease (severe brain trauma, stroke, cerebral tumor…) or current cerebral disease
- Major medical or surgical history
- Current chronic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rapid Visual Information Processing (RVIP) testRapid Visual Information Processing is a measure of sustained attention. | Other | healthy subjects |
Primary outcome
EEG spectral power during RVIP task as compared to resting state
Time frame: within 7 days after inclusion ( session1)
The Rapid Visual Information Processing (RVIP®) is a test of sustained attention and has proved useful in many studies in which drugs are used to help develop a disease model. It is sensitive to dysfunction in the parietal and frontal lobe areas of the brain
5 secondary outcomes
EEG spectral power during PRM task as compared to resting state
Time frame: within 7 days after inclusion ( session1)
RVIP latency of responses
Time frame: within 7 days after inclusion ( session1) and within 7days after session 1 (=session2)
PRM number of errors
Time frame: within 7 days after inclusion ( session1) and within 7 days after session 1 (=session2)
PRM latency of responses
Time frame: within 7 days after inclusion (=session1) and within 7 days after session 1 (=session2)
difference between session 2 and session 1 EEG Spectral power during RVIP task
Time frame: at 7 days after session 1
Results and safety
The study was stopped early (reason given: sponsor decision COVID). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dominique Deplanque, MD, PhD principal investigator
University Hospital, Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rapid Visual Information Processing (RVIP) test in people with Alzheimer Disease and ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder), run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: sponsor decision COVID). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
EEG spectral power during RVIP task as compared to resting state (time frame: within 7 days after inclusion ( session1)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.